

COMUNICATO STAMPA

Labomar becomes “issuer having shares widely spread among the public”

Istrana (TV), February 2, 2022. Labomar ([Euronext Growth Milan, Ticker: LBM](#)) - “Labomar” or the “Company” - nutraceutical company based in Italy with an international business, informs that, on the basis of the results emerging from the Shareholders' Register, the conditions set forth in Article 2-bis of the Issuers' Regulations no. 11971 of 14 May 1999 (the "Issuers' Regulations") required to qualify the Company as an "issuer of financial instruments widely distributed among the public" (the "Diffused Issuer") have been met. In particular, it should be noted that:

- the total number of shareholders, other than the Company's majority shareholders (Walter Bertin through LBM Holding Srl), who together hold at least 5% of Labomar's share capital exceeds 500;
- limits indicated in Article 2435-bis, first paragraph, of the Italian Civil Code have been overcome.

By having acknowledged that the prescribed requirements had been exceeded, Labomar has assumed the status of "issuer with financial instruments widely distributed among the public" and has made the communications required by the Issuers' Regulations to Consob.

Therefore, Labomar will apply the rules of the Issuer in the current financial year.

This press release is available on Labomar's website www.labomar.com – “Investor” section > “Results and Press Releases”.

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years,

Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reports for 2021 preliminary consolidated revenues of approx. Euro 65.4 million (unaudited). Consolidated revenues include - in addition to Labomar Spa and Entreprises ImportFab Inc. - the companies acquired in 2021, i.e. the Welcare Group, from the second half of the year and Labiotre Srl for the month of December only. A 7% increase on 2020 consolidated revenues (of Euro 61.1 million) is reported.

In July 2021, Labomar acquired 63% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of skincare medical devices, with its registered office in Orvieto. In December 2021, the holding increased to 70%.

In November 2021, LaboVar Srl was established - 51% owned by Labomar and 49% by Var Group Spa (a wholly-owned subsidiary of the listed STAR Sesa Spa) - for the sale of nutraceutical products on an e-commerce platform in the Chinese market.

Also in November 2021, Labomar acquired control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by Labomar.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For Information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39.335.7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum +39.02.9049 2525 - ecm@mediolanum.it